Affymax, Inc. and Takeda Pharmaceutical Co. Ltd. Confirm U.S. Registration Strategy for Investigational Drug, Hematide(TM)/Peginesatide, Following Meeting with FDA

PALO ALTO, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE, 4502), today announced that following pre-New Drug Application (NDA) discussions with the U.S. Food and Drug Administration (FDA), the companies will move forward with their regulatory strategy for the investigational drug, peginesatide, for the treatment of anemia in chronic renal failure (CRF) patients on dialysis in the United States.